Most Australians support supervised injecting facilities: study
This Include a Charity Week, consider leaving a gift in your will
Simple measures lessen hospital-acquired COVID-19 infections
New insights into methamphetamine-related deaths in Australia
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
Dynamic nucleolar targeting of dengue virus polymerase NS5 in response to extrac...
20-year trends in Australian methamphetamine-related deaths, 2001-2020.
Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Aus...
GALV-KoRV-related retroviruses in diverse Australian and African rodent species....
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Current Appeal
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing platforms to enhance efficacy of antibodies, Fc-fusion proteins, and antibody-like biologics that have potential application in oncology, infectious disease and immunological conditions.
Find us at BIO 2024 this June.
A hexamerising technology that transforms the potency of monoclonal antibodies (mAb), Fc fusion prot...
